Disclaimer: The following information is for educational and research purposes only. Orforgliperon is an experimental compound, and this is not medical advice or a treatment recommendation.

Overview & Mechanism of Action

Orforgliperon is a novel oral GLP-1 receptor agonist, a class of compounds that mimic the action of glucagon-like peptide-1, a hormone involved in appetite regulation, insulin secretion, and glucose metabolism.

• Mechanism:

  • Activates GLP-1 receptors in the gut and brain.

  • Promotes delayed gastric emptying, leading to increased satiety.

  • Enhances insulin secretion in a glucose-dependent manner.

  • Reduces overall appetite, supporting weight management strategies in research contexts.

Unlike traditional injectable GLP-1 agonists, Orforgliperon’s oral bioavailability makes it easier to integrate into a daily research protocol.

My Personal Protocol (Anecdotal Experience)

• Starting Dose: 3 mg daily

• Timing: Typically taken once per day, either as a standalone or stacked with Reta.

• Titration:

  • Remain at 3 mg for 2–3 weeks to allow the body to adjust.

  • Gradually increase the dose as needed.

  • Maximum dose: ~12 mg daily

  • I typically do not exceed 12 mg, especially when stacking with Reta.

Why I Like It:

• Noticeable appetite suppression without harsh side effects.

• Smooth synergy when stacked with Reta.

• Works well as a daily base compound in a metabolic stack.

Important Considerations

• GLP-1 agonists can cause GI-related effects such as nausea in some cases — slow titration helps minimize this.

• Hydration and protein intake are key during appetite suppression protocols.

• As with all GLP-1 compounds, consistent daily timing seems to provide the best results.